drugset / Trial / NCT06801223

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

NCT06801223

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate pediatric dosing regimens for patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections

Timeline

Start
2026-10-30
Primary completion
2028-05-05
Completion
2028-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Durlobactam Small molecule 20 mg/kg
Subject Durlobactam Small molecule 25 mg/kg
Subject Sulbactam Small molecule 20 mg/kg
Subject Sulbactam Small molecule 25 mg/kg